

REFERENCES

1. Daly JM, Decosse JJ. Principles of surgical oncology. In: Calabrese P, Schein PS, Rosenberg SA, eds. *Medical Oncology*. Toronto, Canada: Macmillan; 1985:261.
2. Fox KR. Surgery in the patient with cancer. In: Goldmann DR, Borwn FH, Guarnieri DM, eds. *Perioperative Medicine: Medical Care of the Surgical Patient*. 2nd ed. New York, NY: McGraw-Hill; 1994;283-293.
3. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation*. 2007;116:1971-1996.
4. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:110S-112S.
5. Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. *Nat Clin Pract Oncol*. 2008;5:655-667.
6. Bdair FM, Graham SP, Smith PF, et al. Gemcitabine and acute myocardial infarction-a case report. *Angiology*. 2006;57:367-371.
7. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. *Eur J Heart Fail*. 2002;4:235-242.
8. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet*. 2007;370:2011-2019.
9. Ewer MS, Benjamin RS. Cardiac complications. In: Bast RC, Kufe DW, Pollock RE, et al, eds. *Cancer Medicine*. 5th ed. London, England: B. C. Decker, Incorporated; 2000:2324-2339.
10. Zambetti M, Moliterni A, Materazzo C, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. *J Clin Oncol*. 2001;19:37-43.
11. Ando M, Yokozawa T, Sawada J, et al. Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation. *Bone Marrow Transplant*. 2000;25:185-189.
12. Kaur A, Yu SS, Lee AJ, et al. Thalidomide-induced sinus bradycardia. *Ann Pharmacother*. 2003;37:1040-1043.
13. Wilke A, Hesse H, Gorg C, et al. Elevation of the pacing threshold: a side effect in a patient with pacemaker undergoing therapy with doxorubicin and vincristine. *Oncology*. 1999;56:110-111.
14. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. *Crit Rev Oncol Hematol*. 2003;45:55-75.
15. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. *Med Phys*. 2002;29:2391-2403.
16. Kelly K, Swords R, Mahalingam D, et al. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. *Target Oncol*. 2009;4:99-105.
17. Lombardi G, Zustovich F, Nicoletto MO, et al. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. *Am J Clin Oncol*. 2009. [Epub ahead of print.]
18. Tashiro M, Izumikawa K, Yoshioka D, et al. Lung fibrosis 10 years after cessation of bleomycin therapy. *Tohoku J Exp Med*. 2008;216:77-80.
19. Einhorn L, Krause M, Hornback N, et al. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. *Cancer*. 1976;37:2414-2416.
20. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. *J Clin Oncol*. 2007;25:3991-4008.
21. Sekine Y, Chiyo M, Iwata T, et al. Perioperative rehabilitation and physiotherapy for lung cancer patients with chronic obstructive pulmonary disease. *Jpn J Thorac Cardiovasc Surg*. 2005;53:237-243.
22. Samama CM, Djoudi R, Lecompte T, et al. Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. *Minerva Anesthesiol*. 2006;72:447-452.
23. Devon KM, McLeod RS. Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery. *Cochrane Database Syst Rev*. 2009(1):CD007148.
24. Hébert PH, Tinmouth A, Corwin HL. Controversies in RBC Transfusion in the Critically Ill. *Chest*. 2007;131:1583-1590.
25. Bauhofer A, Plaul U, Torossian A, et al. Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: a randomized, controlled trial. *Surgery*. 2007;141:501-510.
26. Schaefer H, Engert A, Grass G, et al. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial. *Ann Surg*. 2004;240:68-75.
27. Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. *Curr Opin Oncol*. 2007;19:299-307.
28. Massey E, Paulus U, Doree C, et al. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. *Cochrane Database Syst Rev*. 2009:CD005341.
29. Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. *Clin Infect Dis*. 2006;43:322-330.
30. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. *J Clin Oncol*. 2007;25:5490-5505.
31. National Comprehensive Cancer Network (NCCN). NCCN Practice Guidelines in Oncology. Venous Thromboembolic Disease V.1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf. Accessed December 31, 2009.
32. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:381S-453S.
33. Chun YS, Laurent A, Maru D, et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. *Lancet Oncology*. 2009;10:278-286.
34. Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. *Eur J Cancer*. 1998;34:33-46.
35. Stohr VV, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. *Pediatr Blood Cancer*. 2007;48:140-147.
36. Kintzel PE. Anticancer drug-induced kidney disorders. *Drug Saf*. 2001;24:19-38.
37. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. *Cancer Treat Rev*. 1999;25:47-58.
38. Jones DP, Spunt SL, Green D, et al. Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2008;51:724-731.
39. Kearon C. Antithrombotic therapy for venous thromboembolic disease. *Chest*. 2008;133:454S-545S.

40. Ambiru S, Katob A, Kimura F, et al. Poor postoperative blood glucose control increases surgical site infections after surgery for hepato-biliary-pancreatic cancer: a prospective study in a high-volume institute in Japan. *J Hosp Infect.* 2008;68:230-233.
41. Nieto A, Lozano M, Moro MT, et al. Determinants of wound infections after surgery for breast cancer. *Zentralbl Gynakol.* 2002;124:429-433.
42. Shiono S, Junji Y, Mitsuyo N, et al. Risk factors of postoperative respiratory infections in lung cancer surgery. *J Thorac Oncol.* 2007;2:34-38.
43. Uchiyama K, Takifuji K, Tani M, et al. Prevention of postoperative infections by administration of antimicrobial agents immediately before surgery for patients with gastrointestinal cancers. *Hepatogastroenterology.* 2007;54:1487-1493.
44. Okabayashi T, Nishimori I, Yamashita K, et al. Risk factors and predictors for surgical site infection after hepatic resection. *J Hosp Infect.* 2009;73:47-53.
45. Lotfi CJ, Cavalcanti Rde C, Costa e Silva AM, et al. Risk factors for surgical-site infections in head and neck cancer surgery. *Otolaryngol Head Neck Surg.* 2008;138:74-80.
46. Casey AL, Elliott TS. Progress in the prevention of surgical site infection. *Curr Opin Infect Dis.* 2009;22:370-375.
47. Mueller CK, Schultze-Mosgau S. Radiation-induced microenvironments—the molecular basis for free flap complications in the pre-irradiated field? *Radiother Oncol.* 2009;93:581-585.
48. Deshaies I, Malka D, Soria JC, et al. Antiangiogenic agents and late anastomotic complications. *J Surg Oncol.* 2010;101:180-183.
49. Rettenmaier MA, Abaid LN, Brown JV, et al. Chemotherapy and patient co-morbidity in ventral site hernia development. *J Gynecol Oncol.* 2009;20:246-250.
50. Valentini V, Cassoni A, Marianetti TM, et al. Diabetes as main risk factor in head and neck reconstructive surgery with free flaps. *J Craniofac Surg.* 2008;19:1080-1084.
51. Warren AG, Brorson H, Borud IJ, et al. Lymphedema: a comprehensive review. *Ann Plast Surg.* 2007; 59:464-472.
52. Sahai SK, Wobb J, Manzullo E. The Internal Medicine Perioperative Assessment Center: an innovation in the perioperative management of medical comorbidities at a comprehensive cancer center. *Cleve Clin J Med.* 2006;73(e-suppl 1):S28.
53. Sahai SK, Zalpour A, Rozner MA. Preoperative evaluation of the oncology patient. *Anesthesiol Clin.* 2009;27:805-822.